

### REMARKS/ARGUMENTS

Claims 1-20 are pending in the present patent application. Claims 1-7, and the nucleic acid marker having SEQ ID NO:1 have been elected for examination by the Examiner. Claims 8-20 are withdrawn from consideration, and are cancelled by the present Amendment.


Claim 1 is objected to as including nucleic acid markers that were not elected for examination. In response, claim 1 has been amended to restrict it to the nucleic acid marker having SEQ ID NO:1.

Claims 1-7 are rejected under 35 U.S.C. 112, first paragraph, as not enabling for assessing whether a patient is afflicted with any carcinoma in general. However, the Examiner states that the present application does adequately disclose the increased expression of nucleic acid marker having SEQ ID NO:1 as indicative of ovarian cancer. In response, claims 1-7 have been amended by the present Amendment to recite this specific method.

We gratefully acknowledge that the Examiner has concluded that claims 1-7 are free of the prior art. It is respectfully submitted that claims 1-7, as amended, are now in a condition for allowance, notice of which is earnestly requested.

It is believed that no fees or charges are required at this time in connection with the present application. However, if any fees or charges are required at this time, they may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE LLP

By   
Kent H. Cheng  
Reg. No. 33,849  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770